Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Glucagon-like peptide-1 (GLP-1) receptor agonists as incretin mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors as incretin enhancers are the two classes of incretin-based treatments ...

GLP-1-based therapy: incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 ...

Ricks cited several reasons for the lower-than-expected sales of the incretin mimetics, engineered peptides that work by mimicking gut hormones. December sales usually outperform the rest of the ...

They are in a class of drugs known as incretin mimetics. GLP-1 drugs are more commonly ... GLP-1 drugs may also affect how effective oral birth control pills are. Talk with your healthcare ...

Each person probably has a visceral fat threshold that is genetically determined. Incretin mimetics — GLP-1 receptor agonists and GLP-1/GIP receptor agonists — are the first class of drugs to ...

Eli Lilly LLY1.93%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...